Biogen: Patients Must Be At Center Of UK Biosimilar Decision Making
‘The NHS Is Under Capacity Pressure, We’re Asking For Change,’ Firm Says
The head of biosimilars for Biogen in the UK & Ireland, Jim Porter, sat down with Generics Bulletin to discuss “system challenges and changes that we’re seeing within the UK’s NHS,” as well as Biogen’s own position in what it says is a very important market for the company.
